ResMed result a breath of fresh air
On Wednesday, sleep apnoea treatment manufacturer ResMed (ASX: RMD) revealed strong second quarter results including a 17% increase in revenue compared to the same period of the prior year. In announcing the results, ResMed chief executive Mick Farrell said the company was well positioned to adapt to the Trump administration’s protectionist policies due to its US-based manufacturing operations. RMD shares closed up 9.8% for the week. We hold RMD as a research-driven investment in the WAM Leaders portfolio.
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Wilson Asset Management has a track record of making a difference for shareholders and the community for 27 years and is the investment manager for nine LICs and two unlisted funds. Wilson Asset Management invests over $6 billion on behalf of more than 130,000 retail investors. Wilson Asset Management created and is the lead supporter of the Future Generation companies, the first LICs to deliver both investment and social returns.
1 topic
Wilson Asset Management
Wilson Asset Management has a track record of making a difference for shareholders and the community for 27 years and is the investment manager for nine LICs and two unlisted funds. Wilson Asset Management invests over $6 billion on behalf of more...
Wilson Asset Management
Wilson Asset Management has a track record of making a difference for shareholders and the community for 27 years and is the investment manager for nine LICs and two unlisted funds. Wilson Asset Management invests over $6 billion on behalf of more...
Comments
Comments
Sign In or Join Free to comment
most popular
Funds
8 ETFs with the tick of approval from advisers for FY26
Livewire Markets
Equities
Are CSL's best days behind it?
Livewire Markets